Riskpilot← Back to searchSign inGet full accessVeltio Pharma AB
ABActiveOrg 5591612840UppsalaResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20185-9 employees
Revenue 2024
SEK 78K
EBITDA margin
-3424.4%
+9% vs 2023
Equity ratio
75.4%
Financial strength
Net profit 2024
SEK -2,9M
+5% vs 2023
| Revenue | SEK 78K | — |
| EBITDA | SEK -2,7M | +9% |
| Net profit | SEK -2,9M | +5% |
| Total assets | SEK 2,3M | +15% |
| Equity | SEK 1,7M | +48% |
| Employees | — | — |
Legal name
Veltio Pharma AB
Org number
5591612840
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
4 juni 2018
Share capital
SEK 112 000
Employees
5-9
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas i förening av Bergström, Jon Daniel Mihranyan, Albert Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva farmaceutisk och biomedicinsk forskning och utveckling och där med förenlig verksamhet.
Address
Uppsala
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 78 |
| Staff expenses | — | — | — | — | — | — | — |
| EBITDA | −25 | −21 | −21 | −90 | −2 937 | −2 927 | −2 671 |
| Depreciation & amort. | −8 | −0 | −0 | −0 | −128 | −199 | −292 |
| EBIT | −33 | −21 | −21 | −90 | −3 065 | −3 126 | −2 963 |
| Net financials | — | — | — | — | 2 | 29 | 18 |
| Profit before tax | −33 | −21 | −21 | −90 | −3 063 | −3 097 | −2 945 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −33 | −21 | −21 | −90 | −3 063 | −3 097 | −2 945 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 300 | 534 | 558 | 727 | 1 650 | 2 001 | 2 306 |
| Equity | 267 | 496 | 475 | 636 | 1 271 | 1 174 | 1 739 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 33 | 38 | 83 | 91 | 379 | 826 | 567 |
| Total debt | 33 | 38 | 83 | 91 | 379 | 826 | 567 |
EBITDA margin
-3424.4%
This company
15.8%
Market median
-21773% vs market
20182024
Equity ratio
75.4%
This company
38.2%
Market median
+97% vs market
20182024
Return on equity
-169.4%
This company
18.4%
Market median
-1021% vs market
20182024
Net profit margin
-3775.6%
This company
8.1%
Market median
-46712% vs market
20182024
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
20182024
Debt / equity
0.33×
This company
0.62×
Market median
+47% vs market
20182024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-06-01 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LS Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
EM Chief Auditor | Chief Auditor | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2026 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Veltio Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lisa Stina Katarina Lundgren | Chief Executive Officer | 0 companies |
| Eva Maria Andersson Dverstorp | Chief Auditor | 0 companies |
| Jon Daniel Bergström | Chairman | 0 companies |
| Mats Olof Rickard Johnson | Board of Directors | 0 companies |
| Åsa Rebecca Wallin | Board of Directors | 0 companies |
| John Allan Asp | Board of Directors | 0 companies |
| Albert Mihranyan | Board of Directors | 0 companies |
| Christel Anna Sofie Bergström | Board of Directors | 0 companies |
| Ara Abrahamian | Board of Directors | 0 companies |